GENE ONLINE|News &
Opinion
Blog

2023-06-29| Partnerships

Vertex and Lonza Collaborate to Revolutionize Type 1 Diabetes Treatment

by GeneOnline
Share To

Vertex Pharmaceuticals Incorporated and Lonza have partnered to revolutionize the treatment of type 1 diabetes (T1D). Their collaboration focuses on stem cell-derived islet cell therapies, particularly the VX-880 and VX-264 programs in clinical trials. Vertex is making remarkable progress in the fight against T1D.

In a recent breakthrough, Vertex’s VX-880 program demonstrated clinical proof-of-concept, showing promising results. All six patients treated with VX-880 not only received islet cells but also produced their own insulin (C-peptide) while improving glycemic control. This achievement offers hope for millions living with T1D and paves the way for further treatment advancements.

Related article: Should Weight Loss Seekers Skip Sugar Substitutes?

Manufacturing Collaboration: Vertex and Lonza Working Together

To speed up development and commercialization of their therapies, Vertex and Lonza have formed a strategic partnership. Leveraging Lonza’s expertise in cell and gene technologies and operational excellence, Vertex aims to scale up manufacturing and expand patient access.

The collaboration includes establishing a dedicated facility in Portsmouth, New Hampshire, operated by Lonza. This advanced facility, spanning over 130,000 square feet, is expected to create up to 300 jobs at its peak, demonstrating the commitment of both companies to advancing T1D treatment.

Vertex and Lonza Shaping the Future of Care for Type 1 Diabetes

The partnership between Vertex and Lonza marks a significant milestone in transforming T1D treatment. Vertex’s innovation combined with Lonza’s manufacturing capabilities sets the stage for groundbreaking advancements in the lives of T1D patients worldwide.

With their joint efforts, Vertex and Lonza are determined to push the boundaries of T1D care. Through scientific innovation, manufacturing expertise, and a shared dedication to patients, they chart a new path toward improved outcomes and a brighter future for individuals with T1D.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
FDA Approves Merilog: What It Means for the Diabetes Biosimilar Market
2025-02-19
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
2024-07-11
LATEST
Thermo Fisher Scientific to Acquire Sanofi’s Sterile Manufacturing Facility in Ridgefield, New Jersey
2025-07-17
Rethinking Liver Repair: Cellular Insights and Stem Cell Models Tackle Chronic Disease
2025-07-17
University Hospitals Test Methods to Preserve Unused Donor Hearts for Transplantation
2025-07-17
AI Model Reveals Alzheimer’s Drug Reduces Cognitive Decline by 46% in Early-Stage Patients
2025-07-17
Higher Copper Intake Linked to Improved Cognitive Performance in Older Adults
2025-07-17
Danaher India Partners with THSTI to Enhance Biomanufacturing Skills and Infrastructure in India
2025-07-17
Men Over 75 Now Face Highest Suicide Rates According to CDC Data
2025-07-17
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top